Comparison of Different Diagnostic Criteria of 68Ga-Pentixafor PET/CT for the Classification of Primary Aldosteronism

Xiangshuang Zhang; Furong He; Ying Song; Ying Jing; Jinbo Hu; Hang Shen; Aipin Zhang; Wenwen He; Zhengping Feng; Qifu Li; Hua Pang; Shumin Yang

doi:10.1101/2024.07.26.24311092

Abstract

Background ⁶⁸Ga-Pentixafor positron emission tomography/computed tomography (PET/CT) is an emerging method for the classifying primary aldosteronism (PA). How to use this method for PA classification is still controversial.

Methods A retrospective study was conducted in patients with PA who underwent PET/CT. These patients had a classification diagnosis of unilateral PA (UPA) or bilateral PA (BPA) based on adrenal venous sampling or post-surgical outcomes. Area under the receiver operating characteristic curve (AUC), specificity and sensitivity were used to analyze the accuracy of the lateralization index (LI) based on adrenal maximum standardized uptake value (SUV_max), dominant side SUV_max adjusted by liver, dominant side of SUV_max and visual analysis.

Results A total of 208 PA patients were included, with 128 UPA and 80 BPA. The AUC for diagnosing UPA using LI and visual analysis were 0.82 [95% CI, 0·77-0·87] and 0.82 (95% CI, 0·76-0·87), respectively, higher than the dominant side of SUV_max [0.72, (95%CI, 0·65-0·78)] and dominant side SUV_max adjusted by liver [0.71,(95%CI, 0·64-0·77)]. Visual analysis showed a sensitivity of 0.73 (95%CI,0.65-0.81) and a specificity of 0.88(95%CI,0.80-0.95). The LI cutoff of 1.50 resulted the highest Youden Index of 0.59, with a sensitivity of 0.68 (95%CI,0.59-0.76) and a specificity of 0.91 (95%CI,0.83-0.96). When the LI cutoff was increased to 1.65, the sensitivity reduced to 0.61 (95%CI,0.53-0.70), while the specificity increased to 0.96 (95%CI,0.89-1.00).

Conclusion Both LI and visual analysis of PET/CT could be used in the classification diagnosis of PA. Nevertheless, visual analysis is more sensitive, and LI is more advantageous in specificity.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Because this is a retrospective study, no trial ID was registered

Funding Statement

This work is supported by the National Natural Science Foundation of China (82170825, 82100833 and U21A20355). Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau, 2023MSXM002). National key research & development plan of China, major project of prevention and treatment for common diseases (2022YFC2505300, sub-project: 2022YFC2505301, 2022YFC2505302, 2022YFC2505306). Joint Medical Research Project of Chongqing Science and Technology Commission & Chongqing Health and Family Planning Commission (Major Project, 2022ZDXM003)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

↵† Membership of the CONPASS Group is provided in the Acknowledgments
↵# Shumin Yang, Qifu Li and Hua Pang should be considered joint senior authors.

Data availability

The data that support the findings of this study are available from the corresponding author (Q.L., H.P., and S.Y.), upon reasonable request.

Nonstandard Abbreviations and Acronyms

PA: Primary Aldosteronism
UPA: Unilateral Primary Aldosteronism
BPA: Bilateral Primary Aldosteronism
AVS: Adrenal Venous Sampling
ACTH: Adrenocorticotropic Hormone
LI: Lateralization Index
SI: Selectivity Index
ARR: Plasma Aldosterone/Renin Ratio
PRC: Plasma Renin Concentration
PAC: Plasma Aldosterone Concentration
SUV_max: maximum standardized uptake value

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.